14/10/2025 – The purpose of this virtual conference will be to present in more detail the initial clinical data on the combination of AB8939 + venetoclax in the first three patients with refractory and relapsed AML Download PDF Post navigationPreviousPrevious post:Revenues for the first half of 2025 and update on AB Science’s activitiesRelated PostsRevenues for the first half of 2025 and update on AB Science’s activitiesOctober 10, 2025AB Science announces a slight delay in the publication of its 2025 half-year financial reportSeptember 30, 2025AB Science announces the successful completion of a 2.55 million euros private placementAugust 4, 2025AB Science receives regulatory approval from european countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AMLJuly 30, 2025AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALSJuly 24, 2025AB Science announces the successful completion of a EUR 1.925 million private placementJuly 8, 2025
AB Science announces a slight delay in the publication of its 2025 half-year financial reportSeptember 30, 2025
AB Science announces the successful completion of a 2.55 million euros private placementAugust 4, 2025
AB Science receives regulatory approval from european countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AMLJuly 30, 2025
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALSJuly 24, 2025
